And it is probably around 130M now with even more shorting this past few days. So do the shorts win since they are holding even more shares now? Ooops. Sorry, if you can't cover, you can't win.
fragslap 336 posts | Last Activity: 1 minute 59 seconds ago Member since: Jul 21, 2015
Wow 336 posts in one month! That is an average of 110 posts a day. I hope you get paid by the post. Good luck. Hope you are making a good living.
Sorry I disagree. Ive seen this many times. They've run out of shares to short so they are creating by buying options. Mark this post. Short volume will be up again.
657 posts | Last Activity: 8 minutes ago
Member since: Jul 20, 2015
Why would someone post 657 messages in 45 days, about 17 posts everyday on one stock?
Look at MNKD's inancial statement - as of last quarter they already sold $12M to SNY. But they are reporting everything under "deferred liability" instead of sales. Products don't have to be 'prescribed' to be sold. They sell to pharmacies, not to patients. So even if it is sitting in inventory, it is sales. So your 'sales' based on prescription is what the pharmacies sell, not what MNKD sold.
mmholdem, might I add, Olivier Brandicourt, the former Pfizer executive that brought in Exubera left Pfizer in frustration and became Bayer's CEO and now SNY CEO. You may not know it but Bayer was one of the bidders for the partnership with MNKD - just know it from being in the industry.
and may I add, upon Olivier Brandicourt's departure from Bayer to be SNY's CEO, Bayer sold its entire diabetes business. They were hoping to land Afreeza but having lost to SNY and losing their CEO to SNY, they just threw in the towel for diabetes entirely.
jstockton, the complete story. SNY sold its share of Exubera to Pfizer after MNKD cleared the clinical trials and started making a bid for Afreeza. Check the history books.
Jstockton to complete the story even more. SNY sold its share of Exubera when it became clear that Afreeza was superior. They sold Exubera to make a bid for AFreeza. Then also purchased the Exubera plant in Germany from Pfizer in anticipation of acquiring Afreeza. Check it out.
Rate at Charles Schwab is 16.7%. I got the same email. Like you, I have not received it for a while until now.
Are the five primary care specialist surveyed in India or Philippines? Seems like they like hiring from those places.
Go to the Piper Jaffrey home page. You will see a section on the left for disclosure of company positions. The site will give you a search and type in MNKD. You will see all their ratings since 2013. On March 3/31/2014 they rated MNKD UW: $1.50 (underweight which is their equivalent for "Sell". Shortly thereafter the pps went to over $9.00 (you can see from Piper's chart).
Want to follow Piper's investment advise?
Tier 1 is usually for generic drugs when there is generic. Insulin has generic versions. So Tier 1 will not be possible. In any case, Tier 1 will only drive selling price down. Tier 2 is fine. Nearly all blockbuster drugs are in Tier 2.
Excellent website Mnholden. Thank you for this. From the website:
Total 6,950 Plans
Afrezza vs. Toujeo
Preferred 4% vs 33%
Covered 22% vs 18%
Restricted 42% vs 27%
Not Covered 32% vs. 22%
Considering that Toujeo is just replacing Lantus in all of the plans, this is not too bad of a performance for Afreeza. A note for everyone. Some plans are small and not worth pursuing. Even the good drugs are not entirely covered by every plan. The large ones are the key. Most new drugs, specially if first in its class are placed in 'restricted' because the plans want to make sure the standard of care is not immediately replaced due to reimbursement.
Yes, I agree. Don't cover. Wait until $10. Then cover. It would be sad for shorts to be covering at $3's. it would be wonderful if it's $10 and we still have all these shorts trapped.
kevin, isn't this the small country that will be buying a lot of Afrezza? Straight from Al's mouth.
As I recall it, the global rights given to Sanofi excluded a few small countries, specially Israel. Maybe someone can dig up the exact words from the agreement.
Longs are not selling. This is part of the illusion that shorts are trying to portray. Watch for the short volume report after close tomorrow. Should show an increase. If you can see past the illusion you won't feel so bad. The main reason this is down is the shorts putting in too much supply of shares. Take into account the short shares outstanding of 126M shares when the float is only 240M.
He is. Where do you think the Israeli stock exchange is getting the money from? He is not allowed to own more than 45% of the company. So this is the other way to do it.